Skip to content

Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease

Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease: A Cross-sectional Study in Thai Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02720861
Enrollment
200
Registered
2016-03-28
Start date
2015-03-31
Completion date
2016-06-30
Last updated
2016-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

RNF213 rs112735431 Gene, Acute Non-embolic ischemic stroke

Brief summary

To explore the prevalence of genetic polymorphism on RNF213 rs112735431 gene in non-cardioembolic ischemic cerebrovascular disease in Thai patients.

Detailed description

This is an cross-sectional observational study in Chulalongkorn hospital, to determine the prevalence of genetic polymorphism on RNF213 rs112735431 gene in non-cardioembolic ischemic cerebrovascular disease. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were admitted in Chulalongkorn Hospital for acute ischemic stroke treatment.

Interventions

withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Nationality in Thailand * Age equal or more than 18 years * Clinical and imaging diagnosis of acute ischemic stroke * Patient consent to participate in the research

Exclusion criteria

* High risk for cardioembolic stroke by TOAST classification * Contraindication for venipuncture * Pregnancy or breast feeding patient * History of head and neck radiation * Down's syndrome * Marfan syndrome * Autoimmune disease such as SLE * Ongoing malignancy or remission of malignancy less than 1year

Design outcomes

Primary

MeasureTime frame
Number of Participants With RNF213 rs112735431 Gene polymorphism1 year

Countries

Thailand

Contacts

Primary ContactSuporn Travanichakul, MD
stravanichakul@yahoo.com0858054513

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026